LSV Asset Management Grows Stake in Organon & Co. (NYSE:OGN)

LSV Asset Management grew its holdings in Organon & Co. (NYSE:OGN - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,525,076 shares of the company's stock after acquiring an additional 30,557 shares during the period. LSV Asset Management owned about 2.92% of Organon & Co. worth $112,274,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in OGN. MassMutual Private Wealth & Trust FSB increased its position in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company's stock valued at $41,000 after acquiring an additional 672 shares during the period. Beam Wealth Advisors Inc. grew its position in shares of Organon & Co. by 3.9% in the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company's stock valued at $282,000 after purchasing an additional 717 shares during the last quarter. HighTower Advisors LLC lifted its stake in shares of Organon & Co. by 0.5% in the fourth quarter. HighTower Advisors LLC now owns 163,440 shares of the company's stock valued at $2,439,000 after buying an additional 855 shares during the period. CIBC Asset Management Inc boosted its position in shares of Organon & Co. by 4.9% during the 4th quarter. CIBC Asset Management Inc now owns 25,523 shares of the company's stock valued at $381,000 after acquiring an additional 1,184 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Organon & Co. by 24.3% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 6,256 shares of the company's stock worth $93,000 after purchasing an additional 1,222 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on OGN shares. Morgan Stanley cut their price target on Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating on the stock in a research note on Wednesday, April 9th. TD Cowen upgraded shares of Organon & Co. to a "hold" rating in a report on Wednesday, January 15th. Finally, Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Organon & Co. currently has a consensus rating of "Hold" and an average target price of $20.60.

Organon & Co. Stock Performance

NYSE OGN remained flat at $11.05 on Wednesday. The company's stock had a trading volume of 1,045,081 shares, compared to its average volume of 2,647,489. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 3.32, a P/E/G ratio of 0.90 and a beta of 0.73. The firm's 50-day simple moving average is $14.48 and its 200-day simple moving average is $15.56. Organon & Co. has a 1-year low of $10.90 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. On average, research analysts forecast that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 10.14%. Organon & Co.'s dividend payout ratio is currently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.